The firm has partnered with Illumina to use the Dragen Bio-IT informatics platform to help customers analyze data from the new Cancer Transcriptome Atlas panel.
Exome sequencing had lower sensitivity and specificity for finding inborn errors of metabolism than conventional screening, but appeared to refine mass spec-based results.
The report also identified opportunities to improve adoption through dissemination of evidence supporting the clinical and economic utilization of testing.
The Washington Post writes that the approval in the US of a SARS-CoV-2 vaccine will be up to Peter Marks, a career official at the Food and Drug Administration.
